Cost Effectiveness of High-Dose Chemotherapy with Autologous Stem Cell Support as Initial Treatment of Aggressive Non-Hodgkinʼs Lymphoma-Reference-Cited by-同舟云学术

Cost Effectiveness of High-Dose Chemotherapy with Autologous Stem Cell Support as Initial Treatment of Aggressive Non-Hodgkinʼs Lymphoma

Published:2009 Issue:1 Volume:27 Page:55-68
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Fagnoni Philippe,Milpied Noel,Limat Samuel,Deconinck Eric,Nerich Virginie,Foussard Charles,Colombat Philippe,Harousseau Jean-Luc,Woronoff-Lemsi Marie-Christine

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pharmacology

Reference34 articles.

1. Aggressive Non-Hodgkin???s Lymphoma

2. Hematopoietic Stem-Cell Transplantation

3. State-of-the-Art Therapeutics: Diffuse Large B-Cell Lymphoma

4. Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma

5. Survival Benefit of High-Dose Therapy in Poor-Risk Aggressive Non-Hodgkin’s Lymphoma: Final Analysis of the Prospective LNH87–2 Protocol—A Groupe d’Etude des Lymphomes de l’Adulte Study

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Versus BEAM (Carmustine, Etoposide, Cytarabine, Melphalan) as Conditioning Regimen Before Autologous Haematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis;Cell Transplantation;2023-01

2. Cryopreserved versus non-cryopreserved stem cell autografts in multiple myeloma a restrospective cohort study;Bone Marrow Transplantation;2022-05-30

3. Positron-emission tomography-based staging is cost-effective in early-stage follicular lymphoma;Journal of Nuclear Medicine;2021-08-19

4. Plerixafor in poor mobilizers with non-Hodgkin’s lymphoma: a multi-center time-motion analysis;Bone Marrow Transplantation;2017-12-18

5. Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: A cost-effectiveness analysis;Cancer;2015-04-15